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Background: The presence and extent of structural changes in the brain as a consequence of Parkinson’s disease
(PD) is still poorly understood.
Methods: High-resolution 3-tesla T1-weighted structural magnetic resonance images in sixty-five PD and 27
age-matched healthy control participants were examined. Putamen, caudate, and intracranial volumes were
manually traced in the axial plane of 3D reconstructed images. Striatal nuclei volumes were normalized to
intracranial volume for statistical comparison. Disease status was assessed using the Unified Parkinson’s Disease
Rating Scale and Hoehn and Yahr scale. Cognitive status was assessed using global status tests and detailed
neuropsychological testing.
Results: Both caudate and putamen volumes were smaller in PD brains compared to controls after adjusting for
age and gender. Caudate volumes were reduced by 11% (p = 0.001) and putamen volumes by 8.1% (p = 0.025). PD
striatal volumes were not found to be significantly correlated with cognitive or motor decline.
Conclusion: Small, but significant reductions in the volume of both the caudate and putamen occur in PD brains.
These reductions are independent of the effects of age and gender, however the relation of these reductions to
the functional loss of dopamine, which is characteristic of PD, remains unclear.
Keywords: Magnetic resonance imaging, Volumetry, Caudate, Putamen, Parkinson’s diseaseBackground
The striatum (caudate and putamen) is the major input
structure of the basal ganglia complex and is an essential
part of neural networks involved in motor and non-
motor function [1]. Striatal function is severely impaired
in Parkinson's disease (PD), which depletes the neuro-
modulatory influence of ventral midbrain dopamine-
producing neurons on these circuits and disrupts the
balance of multiple corticostriatal circuits.
It is, however, unclear whether PD also produces gross
morphological (volumetric) changes in the striatum. PD
manifests progressively worsening motor and non-motor
(cognitive and behavioral) dysfunction, which may in
part reflect anatomical changes at the level of the puta-
men (motor) and caudate (oculomotor, cognitive and* Correspondence: toni.pitcher@otago.ac.nz
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reproduction in any medium, provided the orbehavioral). Previous magnetic resonance imaging (MRI)
studies have variously reported decreased or non-
significant volume differences for these striatal struc-
tures using manual or semi-automated tracing methods
[2-8] (Table 1).
We employed 3-tesla MRI to estimate in vivo volumes
of the striatum, using a large sample that covered a wide
range of the motor and cognitive changes evident in PD.Methods
Participants
A total of 116 participants, 82 with a diagnosis of probable
PD according to the UK Brain Bank criteria [9] and 34
healthy age-related controls were recruited as part of a
continuing research programme. PD participants were
recruited through a movement disorder clinic (TJA) and
healthy controls were volunteers from the general popula-
tion. Exclusion criteria were a history of another central
nervous system disorder, such as stroke or head injury orLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Summary of studies investigating striatal and total brain volumes in Parkinson’s disease using manual tracing
and semi-automated methods
Study Magnet strength Slice thickness N PD/Control TBV/ICV (effect size) CN (effect size) PUT (effect size) Other
Lisanby. et al., 1993. [6] 1.5 T 5.0 mm 21/21 - # (−1.4) # (−1.8) # Thal
Schulz. et al., 1999. [8] 1.5 T 0.9 mm 11/46 - ↔ ↔ -
Ghaemi. et al., 2002. [4] 1.0 T 2.0 mm 24/17 - ↔ (0.77) ↔ (0.34) -
O’Neill. et al., 2002. [7] 1.5 T 1.4 mm 10/13 ↔ (0.41) ↔ # (−0.89) # GP
Almeida. et al., 2003. [2] 1.5 T 1.6 mm 28/35 ↔ (0.003) ↔ (−0.02) - -
Krabbe. et al., 2005. [5] 1.5 T 1.7 mm 21/19 " (0.47/0.75) ↔ (−0.08) # (−0.99) # SN
Geng. et al., 2006. [3] 3.0 T 2.0 mm 16/8 ↔ (−0.38) ↔ (−0.57) # (−1.5) ↔ SN # GP
Current study 3.0 T 1.0 mm 65/27 ↔ (−0.13) # (−0.80) # (−0.52)
Direction of difference: " significant increase in volume,↔ no significant change in volume, # significant decrease in volume in PD compared to healthy controls.
- Structure not investigated. Standardized effect sizes (in parentheses) were calculated where sufficient information was available. Negative values indicate PD
volumes smaller than controls.
TBV total brain volume, ICV intracranial volume, CN caudate nucleus, PUT putamen, Thal thalamus, GP globus pallidus, SN substantia nigra pars compacta.
Geng et al. [3] decrease in GP between late PD (n = 8) and controls only. Krabbe et al. [5] ICV effect sizes represent the supratentorial and infratentorial (supra/infra
in table) volumes which were measured separately.
Table 2 Demographic and clinical characteristics of study
participants
PD (n= 65) Control (n = 27)
Male/female (n) 48/17 19/8
Age (years) 66.2 ± 9.4 68.7 ± 9.6
Education (years) 12.8 ± 2.9 13.4 ± 2.9
MMSE 28.0 ± 2.7 29.0 ± 1.1
MoCA 23.9 ± 5.1 27.0 ± 1.9
Symptom duration (years) 6.3 ± 5.7
range 0.5-30
UPDRS part III 33.7 ± 16.3 -






PD Medication Status (n)
No medication 24
On Medication 41
LED (mg/day) 572.4 ± 339.5
Values are expressed as mean ± standard deviation, unless otherwise stated.
MMSE Mini Mental State Examination, MoCA Montreal Cognitive Assessment,
UPDRS Unified Parkinson’s Disease Rating Scale, H & Y Hoehn and Yahr scale,
MCI mild cognitive impairment, LED levodopa equivalent dose.
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participants underwent structural magnetic resonance
scanning, clinical and cognitive assessment. Six (4 PD and
2 controls) did not meet the requirements of a standard
magnetic resonance safety screen and were excluded. A
further eighteen were subsequently excluded, five (3 PD
and 2 controls) following clinical review of scans, three
controls who met the criteria for mild cognitive impair-
ment (MCI) and ten (all PD participants) because of the
presence of lacunar infarcts or large perivascular spaces in
the striatal or internal capsule regions (n= 6) or move-
ment artefacts (n= 4). Demographic and clinical character-
istics of the final cohort (PD n=65 and control n = 27)
included in this study are provided in Table 2. The Upper
South Regional Ethics Committees, New Zealand,
approved all procedures and all participants gave informed
written consent.
PD participants underwent assessment of PD symptom
severity and disease stage using the Unified Parkinson’s
Disease Rating Scale (UPDRS) [10] and the modified
Hoehn and Yahr scale (H & Y) [11]. Participants were
classified as having dementia, mild cognitive impairment
(MCI) or being of normal cognition using the following
battery of tests. Attention and working memory: digits
forward and backward, digit ordering, map search, Trails
A, Stroop colour and word naming; Executive function:
letter, action and category fluency, and category switch-
ing, Trails B and Stroop interference; Visuospatial and
perception: judgement of line orientation, fragmented
letters and Rey-Osterrieth Complex Figure copy; Learn-
ing and memory: California Verbal Learning Test–Short
Form and the Rey-Osterrieth Complex Figure Test. A
dementia diagnosis followed the Movement Disorders
Task Force criteria [12], requiring significant impairment
in activities of daily living [13] and severe impairment
(two or more standard deviations below normative data)in two or more cognitive domains. Mild cognitive im-
pairment was defined as a score of 1.5 or more standard
deviations below the normative score in at least two
tests in one neuropsychological domain [14] and meets
the Movement Disorders Task Force guidelines for MCI
[15]. Global cognitive status was assessed with the Mini
Mental State Examination (MMSE) [16] and Montreal
Cognitive Assessment (MoCA) [17] (not available in 3
Pitcher et al. Translational Neurodegeneration 2012, 1:17 Page 3 of 8
http://www.translationalneurodegeneration.com/content/1/1/17PD participants). The levodopa-equivalent dose (LED)
for PD participants was calculated using previously pub-
lished conversion factors [18-20].
Image acquisition
Structural magnetic resonance images were acquired
with a 3.0-tesla General Electric HDx scanner (GE
Healthcare, Milwaukee, WI, USA) using a high-
resolution 3D T1-weighted spoiled gradient recalled ac-
quisition sequence: echo time = 2.8 ms; repetition
time = 6.6 ms; inversion time = 400 ms; flip angle = 15°,
slice thickness 1 mm, field of view = 250 x 250 mm2, ac-
quisition matrix 256 x 256 and voxel size of 0.98 x 0.98
x 1 mm3. Reconstructed images with a matrix of 512 x
512 and voxel size 0.5 x 0.5 x 1 mm3 were used for the
manual segmentation of regions of interest (ROI).
Region of interest (ROI) manual tracing
Manual tracing of ROIs was performed by a single rater
(TLP) using reconstructed images in MRIcroN [21]
(http://www.mricro.com) implemented on a Windows
PC. The rater was blinded to group membership. ROIs
were traced in the axial plane with sagittal and coronal
planes used for reference using the guidelines below.
Each ROI was saved as a single volume, example tra-
cings are shown in Figure 1.
Putamen ROI
Tracing of the putamen began in the first slice in which
the putamen was clearly separated from the head of the
caudate by the anterior limb of the internal capsule. Tra-
cing continued on sequential slices for as long as a
clearly distinguishable patch of grey matter was visible
below the corona radiata. The globus pallidus and anter-
ior limb of the internal capsule served as the medial
border and the external capsule as the lateral border.
Care was taken to ensure the claustrum was excluded.
Caudate nucleus ROI
The caudate was divided into two parts, head and body,
which were traced separately. Tracing of the head of the
caudate began in the first slice in which the internal cap-
sule clearly separated the caudate from the putamen and
in which the cavity of the lateral ventricle was visible.
All gray matter below this slice was considered part of
the nucleus accumbens. Small protuberances were
included in the measurements of the head of the caudate
as described by Looi et al. [22]. The boundary between
the caudate head and body was defined, in the coronal
view, as the first slice in which the interventricular for-
amen was present [23], i.e. when the cavities of the lat-
eral and third ventricle were seen to be continuous. An
ROI, covering the entire coronal slice at this level, was
created and overlaid on the image, giving a horizontalline across the axial slice. Regions of caudate above to
the line were designated the head, and regions below,
designated the body. The medial border of the caudate
was the cavity of the lateral ventricle. The lateral and su-
perior borders of the caudate were the white matter of
the internal capsule and corona radiata, respectively.
The gray matter projections between the head of the
caudate and the putamen, seen crossing the anterior
limb of the internal capsule, were not included in the
volume estimates of either nuclei. The caudate nucleus
head and body were unable to be accurately delineated
in six participants (PD n= 4, controls n = 2) due to the
participants head position during scanning. Whole caud-
ate nucleus volumes from these participants were
included in the final analysis.
Intracranial volume
The intracranial volume (ICV) was manually traced in
the axial view on every tenth section with intervening
slices interpolated [24]. The ICV was traced between the
foramen magnum and brain vertex. A starting slice
within these boundaries was randomly selected for each
brain. The outline was traced following the inner layer
of the dura where visible, and the contour of the brain
where dura was not visible. The venous sinuses and pi-
tuitary fossa were excluded from the ICV calculation.
ROI volume calculation
A custom Matlab (The MathWorks Inc, Natick, USA)
script was used to count the number of voxels in each
ROI. This value was then multiplied by the recon-
structed voxel size to give the ROI volume in mm3. Stri-
atal volumes were normalized to the intracranial volume
(bilateral structure volume/ICV x 100%) for statistical
comparison.
Statistics
Statistical analyses were conducted using SPSS 17 (SPSS
Inc, Chicago) using normalized volumes (significance
was set at p < 0.05). Analysis of covariance was used to
compare ICV normalized volumes with group and gen-
der as fixed factors and age as a covariate. Effect sizes
were calculated from the estimated marginal means pro-
duced by the analysis of covariance. Associations be-
tween volumes, demographic and clinical variables were




There was no difference in the age (F(1,91) = 1.39;
p = 0.241) or years of education (F(1,91) = 0.947;
p = 0.333) between PD and control groups (Table 2).
There was a significant difference in MoCA scores
Figure 1 Putamen and caudate volumes. Continuous slices showing the full volumes of the left putamen and caudate in a brain of a
Parkinson’s disease participant. a; putamen, b; caudate head, c; caudate body. Horizontal line; division between the caudate head and body. Line
was defined in the coronal view at the level of the interventricular foramen.
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3.41; p= 0.068).
ROI measurement reliability
The reliability of volumetric measurements was assessed
by randomly selecting 15 scans, duplicating them and
including them within the larger sample. The rater wasblinded to this process. The reliability of ROI tracing
was calculated using raw voxel size measurements from
the duplicate scans and the intraclass coefficient statistic.
Reliability coefficients were: right putamen, 0.99; left pu-
tamen, 0.96; right caudate head, 0.97; right caudate body,
0.87; left caudate head, 0.99; left caudate body, 0.97; and
ICV, 0.99.
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Intracranial volume did not differ between PD and healthy
controls. (Control; mean ± sd. 1524.5±177 cm3, PD;
1546.7±159 cm3; F(1,91)=0.35, p=0.56, effect size=−0.13).
The volumes (mm3) of each ROI and of the total (left
+ right) putamen and caudate are shown in Table 3. To
control for global differences in head size, striatal
volumes were normalized to the ICV (see Table 3).
Analysis of normalized striatal nuclei volumes indicated
that both the caudate and putamen were smaller in PD
compared to controls (Table 4), representing a 11% vol-
ume reduction in the caudate and an 8.1% volume reduc-
tion in the putamen. The model controlled for gender and
age, with marginal means calculated assuming an age of
67 years, the average for the entire sample. Although both
the caudate head and body showed reductions in volume
only the head volume was significantly smaller in PD com-
pared to controls (Table 4).
Both age and gender were found to have significant
effects on striatal nuclei volume. Age effects were greatest:
caudate; F(1,91) = 14.6, p < 0.001 and putamen; F
(1,91) = 39.5, p < 0.001. Regression analysis estimated the
volume losses to be 28 mm3/year in the caudate and
57 mm3/year in the putamen. The gender effect indicated
that females had larger striatal volumes, with the caudate
but not the putamen reaching significance (see Table 4).
There were no group by gender interactions: caudate; F
(1,91) = 0.325, p = 0.57, putamen; F(1,91) = 0.01, p = 0.92.
Antiparkinsonian medications were not found to have
an effect on striatal size: caudate; F(1,64) = 0.30, p = 0.56,
putamen; F(1,64) = 2.66, p = 0.11.
Effect of clinical and cognitive measures
Effect sizes slightly smaller than those obtained in the
full sample comparison were obtained when comparing
cognitively normal PD participants (n = 41) to healthyTable 3 Raw and normalized ROI volumes
PD (n= 65)
Brain region Volume (mm3) Normalized volum
R Putamen 3200.9 ± 600.3 0.208 ± 0.03
L Putamen 3238.0 ± 560.0 0.210 ± 0.03
R Caudate Head 2680.6 ± 436.5 0.173 ± 0.02
R Caudate Body 577.4 ± 176.0 0.037 ± 0.01
L Caudate Head 2627.4 ± 427.2 0.170 ± 0.02
L Caudate Body 530.5 ± 170.3 0.034 ± 0.01
Total R Caudate 3226.0 ± 534.7 0.210 ± 0.03
Total L Caudate 3120.8 ± 541.8 0.202 ± 0.03
Total Putamen (L + R) 6438.9 ± 1092.4 0.418 ± 0.06
Total Caudate (L + R) 6346.8 ± 1059.2 0.411 ± 0.06
ICV 1,546,729.1 ± 159,539.4
ICV intracranial volume, L left, R right, PD Parkinson’s disease.controls, although the putamen no longer reached sig-
nificance (see Table 4). There was no significant differ-
ence in striatal volumes between the PD cognitive
groups (Caudate: PD-normal, 0.419 ± 0.060; PD-MCI,
0.411 ± 0.058; PDD, 0.380 ± 0.057. F(1,64) = 0.64, p = 0.53.
Putamen: PD-normal, 0.429 ± 0.068; PD-MCI,
0.393 ± 0.048; PDD, 0.407 ± 0.071. F(1,64) = 0.99,
p = 0.38). There were no significant differences in striatal
volumes between patients with the initial onset of motor
symptoms on the left versus the right (analysis restricted
to early stage PD; H & Y stage 1 to 2.5 and cognitively
intact). There was no association between striatal
volumes and total UPDRS part III motor score. There
was also no association when the UPDRS scores were
separated into left and right-sided items and correlated
with the contralateral striatal volumes. There was an
overall correlation between striatal volumes and H & Y
stage (Figure 2: caudate: r =−0.36, p = 0.004 and puta-
men: r =−0.27, p = 0.03). The variability within each H &
Y stage meant that there were no significant differences
between individual stages. Striatal volumes were also
correlated with MoCA scores (Figure 2: caudate:
r = 0.32, p = 0.010 and putamen: r = 0.289, p = 0.02) but
not MMSE or disease duration.
Given the significant influence of age and gender on
striatal volumes the significant correlations were retested
using partial correlational analyses controlling for these
factors, following which, no significant associations were
observed (caudate: H & Y stage; r =−0.20, p = 0.13.
MoCA; r = 0.11, p = 039, and putamen: H & Y; r = 0.00,
p = 1.0, MoCA; r = 0.03, p = 0.80). The association be-
tween striatal volumes and age is shown in Figure 2. Be-
cause age, cognitive status and disease severity are
highly correlated with each other, it is difficult to deter-
mine which factors are primarily driving the association
with striatal volume.Control (n = 27)
e (%ICV) Volume (mm3) Normalized volume (%ICV)
9 3301.3 ± 604.0 0.219± 0.045
5 3409.1 ± 663.2 0.226± 0.050
5 2739.8 ± 409.8 0.183± 0.032
1 616.6 ± 210.7 0.041± 0.013
6 2697.6 ± 357.41 0.180± 0.030
0 577.2 ± 167.9 0.038± 0.009
0 3490.3 ± 686.3 0.230± 0.041
1 3392.6 ± 587.1 0.224± 0.036
6 6710.5 ± 1239.6 0.445± 0.093
7 6882.9 ± 1250.4 0.454± 0.076
1,524,478.5 ± 177,354.4
Table 4 Results of striatal volume comparisons
Striatal Regionψ PD (n = 65) Healthy Controls (n = 27) F(1,91) p Effect size
Normalized Caudate 0.416% (0.400 – 0.433) 0.468% (0.443 – 0.493) 11.38 0.001 −0.80
Normalized Putamen 0.422% (0.405 – 0.440) 0.459% (0.432 – 0.442) 5.22 0.03 −0.52
Gender effectsψ Male (n = 67) Female (n = 25) F(1,91) p Effect size
Normalized Caudate 0.423% (0.407 – 0.439) 0.461% (0.435 – 0.487) 6.2 0.02 −0.59
Normalized Putamen 0.425% (0.408 – 0.442) 0.456% (0.429 – 0.483) 3.8 0.05 −0.47
Caudate sub-regionsζ PD (n = 58) Healthy Controls (n = 25) F(1,82) p Effect size
Normalized Head 0.351% (0.338 – 0.363) 0.381% (0.363 – 0.399) 7.4 0.008 −0.66
Normalized Body 0.071% (0.064 – 0.077) 0.078% (0.070 – 0.086) 2.0 0.16 −0.32
Cognitively normal comparison* PD normal cognition (n= 41) Healthy Controls (n = 27) F(1,67) p Effect size
Normalized Caudate 0.424% (0.401 – 0.446) 0.470% (0.442 – 0.497) 6.0 0.02 −0.65
Normalized Putamen 0.429% (0.406 – 0.453) 0.465% (0.437 – 0.494) 3.9 0.05 −0.48
Values are estimated marginal means (95% confidence intervals) calculated from analysis controlling for gender and age.
ψAssumed age of 67 years; ζAssumed age of 66.4 years; *Assumed age of 65.7 years.
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Decreased volumes of both the caudate and putamen were
found in PD brains compared to healthy controls. This
study provides the first 3-tesla evidence of caudate atrophy
in PD brains, using manual tracing methods. The present
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Figure 2 Association between striatal volumes and clinical measures.
normal cognition (PDN), mild cognitive impairment (PD-MCI), or dementia
associated with overall cognitive status, as assessed by the Montreal Cogni
structures decreased in volume with increasing motor disease severity, as m
both structures decreased with age. The striatal associations with both MoC
collinearity of the predictors, however, (i.e., older patients were more likely
makes the attribution of causality difficult. Striatal volumes are expressed asand in which, reduced putamen volumes but not caudate
volumes were reported [2-5,7,8]. A possible source of vari-
ation in the findings across previous studies is variation in
imaging parameters, including magnet strength, scanning
sequence, slice thickness and inter-slice gap. The present
study has the advantage of enhanced image resolution& Yahr stage
3 4
Age
50 60 70 80
Each circle represents one Parkinson’s disease patient, either with
(PDD). Left column: The volume of each striatal structure was positively
tive Assessment (MoCA, maximum score = 30). Middle column: Both
easured by the Hoehn & Yahr scale. Right column: The volume of
A and Hoehn & Yahr did not survive correction for age. The clear
to be cognitively impaired and to have worse motor impairment)
percentage of intracranial volume (%ICV).
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1 mm-thick slices with no inter slice gap, enabling the full
extent of the regions of interest to be viewed. Another po-
tential source of variation may be the boundaries used to
delineate each structure. Although the putamen and caud-
ate have well-defined boundaries due to the surrounding
white matter and lateral ventricles, these structures fuse
anteriorly with the ventral striatum. Unfortunately, most
previous studies do not give detailed descriptions of the
boundaries used.
A volume reduction in the putamen has previously
been accepted due to the reduced dopaminergic activity
in the nucleus in early disease stages [3,4,7], but little at-
tention has been given to potential mechanisms of such
a reduction. Although MRI is not able to directly inform
us on such mechanisms, post-mortem studies provide
some insight. A reduction in the dendritic spine density
and a shortening of dendritic length in the medium
spiny neurons of the striatum [25,26], and frank loss of
striatal cells [27] have been described in post-mortem
tissue. Such changes may contribute to a volume reduc-
tion and could significantly influence the functionality of
the vast cortical projections to the striatum, which syn-
apse on the medium spiny neuron dendritic arbour.
Whether these events occur as a direct result of dopa-
mine loss is unclear.
The volume reduction in the caudate was greatest in
the head of the nucleus with non-significant volume
changes in the body. The head of the caudate is more
involved in cognitive function than the body, which is
primarily involved in oculomotor function. However, our
results do not suggest that the volume loss in the caud-
ate is associated with cognitive status, as we also
observed reduced caudate volume when comparing the
cognitively unimpaired PD participants to healthy con-
trols and no significant changes in volume between the
PD cognitive groups. Whether caudate volume loss con-
tributes to an increased susceptibility to later cognitive
decline remains unknown.
Aside from Ghaemi et al. [4] all earlier studies from
which we were able to calculate effect sizes indicated the
putamen and caudate volumes to be smaller in PD
brains compared to control brains (Table 1). The effect
size for the caudate volume decrease in the study by
Geng et al. [3] was of a reasonable size, but no signifi-
cant reduction in PD volume was reported, suggesting
that the study may have been underpowered to detect
the difference in this measurement. Given the
consistency in direction of effect sizes across previous
studies, and the large sample used in our study, we be-
lieve our results reflect true changes in striatal volume
in PD.
The absence of an effect of laterality of symptoms
(whether side of initial onset or currently most affectedside) upon striatal volume is consistent with previous
studies [3]. The lack of association between striatal
volumes and disease stage indicates that continued loss
of volume over time due to disease processes may be of
a relatively small magnitude and unable to be teased
apart from the losses associated with increasing age.
This is in contrast to the previously reported negative
association between putamen volume and H & Y stage
[3]. Since H & Y stage was significantly correlated with
age in this current study, and the correlation between H
& Y stage and volumes was not present after correcting
for age, the association reported previously may have
been, at least in part, due to age rather than more
advanced stages of PD. Further investigation into the re-
lationship between disease stage and striatal volume
would require greater numbers of younger people with
more advanced symptoms. Nigro-striatal neuronal loss is
approximately 60% by the time of symptom onset [28]
with rates of loss greater in earlier rather than late stages
of the disease. Thus, it should not be surprising that we
observed a significant reduction in striatal volumes in
patients with normal cognition and no significant change
with advancing disease (as measured by H & Y stage).
A limitation to the study is the unbalanced sample
sizes in the cognitive sub-groups. Increased numbers of
MCI and dementia PD participants would strengthen
the analysis based on cognitive status. Also, improved
delineation of the sub-regions of the caudate may be
achieved in the future with the utilisation of diffusion
tensor imaging tractography.
In summary, we have provided evidence at 3-tesla, that
the caudate and putamen undergo volume loss in Par-
kinson’s disease, even early in the disease course. These
new data, in conjunction with the existing literature,
confirm the presence of atrophy in the striatum in PD
brains over and above the influence of natural aging, al-
though not with declining cognitive function and in-
creasing motor impairment. Given the overlap in
volumes across groups, such measures would not be
useful as a diagnostic tool, however, knowledge of such
volume reductions is important for understanding dis-
ease effects on the brain.
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